Search

Your search keyword '"Willekens, Christophe"' showing total 226 results

Search Constraints

Start Over You searched for: Author "Willekens, Christophe" Remove constraint Author: "Willekens, Christophe" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
226 results on '"Willekens, Christophe"'

Search Results

1. Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

2. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials

3. A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia.

4. CXCL8 secreted by immature granulocytes inhibits wildtype hematopoiesis in chronic myelomonocytic leukemia

5. RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives.

6. Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

7. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

8. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia

10. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

11. When monoclonal gammopathy‐associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes

12. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice

13. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

14. Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

15. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

16. RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies

17. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

19. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice

20. Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

23. SRSF2-P95Hdelays Myelofibrosis Development through Altered JAK/STAT Signaling in JAK2-V617F Megakaryocytes

24. Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

27. Evolution clonale: qu’est-ce qu’un clone?

28. Coopération entre les mutations Jak2 V617F et Srsf2 P95Hdans le système hématopoïétique

29. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study

30. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

31. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study

32. Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening

33. ATG2B/GSKIP in de novo acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies

34. Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin’s lymphoma not eligible for intensive chemotherapy

38. Abstract PO-030: Outcome of older cancer patients infected with Covid19 at Gustave Roussy Cancer Center

39. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

40. Abstract CT403: Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments

41. 5-Azacitidine in patients with IDH1/2-mutant recurrent glioma

42. High‐dose cyclophosphamide for hard‐to‐treat patients with relapsed or refractory B‐cell non‐Hodgkin's lymphoma, a phase II result

43. Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

44. CHIP in the molecular landscape of TRMN

45. A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset

46. Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case report.

47. ATG2B/Gskip in De Novo Acute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML

48. Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening.

49. The Impact of Risk-adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplant

50. Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study

Catalog

Books, media, physical & digital resources